



FOR IMMEDIATE RELEASE

**APPOINTMENT OF MS. ZHANG ZHEN HUA, ADA
AS GROUP DIRECTOR OF HUMAN RESOURCES AND DEVELOPMENT
OF LEE'S PHARMACEUTICAL HOLDINGS LIMITED**

Hong Kong, China (3 October 2017) – Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group") today announced that Ms. Zhang Zhen Hua, Ada ("Ms. Zhang") had been appointed as Group Director of Human Resources and Development ("Group HR Director") of Lee's Pharmaceutical Holdings Limited, based in Guangzhou and Hong Kong, with effect from 1 October 2017.

"We are glad to have Ms. Zhang on board as the Group HR Director and we believe Ms. Zhang will provide valuable human resources supports to the Group, such as human resources strategic plans, to assess, develop, recruit and retain staff of the right calibre, and optimize the overall remuneration and welfare structure and grading system, and reward mechanism, etc." said Dr. Li Xiaoyi, Chief Executive Officer of Lee's Pharm, "and we are confident that Ms. Zhang will disseminate and execute all relevant strategies, policies and procedures among business units of the Group effectively."

Ms. Zhang holds a Master's degree of business administration from the Southern Cross University Australia, has more than 25 years of working experience in multinational corporations and with broad knowledge and experience in human resources management. Ms. Zhang had worked for companies such as Watson's Group, Total Group, BP, PepsiCo, Wyeth Pharmaceuticals, and Novartis. Prior to joining Lee's Pharm, she was the HRBP director at Takeda Pharmaceuticals.

About Lee's Pharm

Lee's Pharm is a research-based biopharmaceutical company listed in Hong Kong with more than 20 years of operation in China's pharmaceutical industry. It is fully integrated with a strong infrastructure in drug development, manufacturing, sales and marketing. It has established extensive partnerships with more than 20 international companies and currently has 15 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. The Group's development program is lauded with over 40 product candidates stemming from both internal R&D efforts and collaborations with US, European and Japanese companies, including promising compounds to treat liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Additional information is available at <http://www.leespharm.com>.



FOR IMMEDIATE RELEASE

Safe Harbour Statement

The performance and the results of operation of Lee's Pharm during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's Pharm. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's Pharm nor the Directors, employees or agents of Lee's Pharm assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialize or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com